Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Involved Vehicles for Seniors: Track down the Best Picks for Solace and Unwavering quality - 2Curl Up With Some Hot Chocolate And Watch Mighty Car Mods Explore Japan In A Honda City Turbo II
- 3IDF uncovers 7 km.-long Gaza terror tunnel where Hamas held Hadar Goldin
- 437 Things Just Individuals Experiencing childhood during the 80s Will Comprehend
- 5West Palm Beach Shorecrest, renderings of downtown waterfront condo
- Display of Netanyahu's severed head 'incites public to murder PM', Likud says in official complaint
- Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- How to watch the 2025 Macy's Thanksgiving Day Parade for free
- Email Promoting Instruments for Compelling Efforts
- Little Italy Mercato brings fresh food and community to downtown San Diego
- How to watch ‘The Traitors’ Season 4: Premiere date, episode release time, full cast list and more
- Rebecca Gayheart on her 'very complicated' relationship with Eric Dane: 'I am always going to want the best for him'
- Skeleton of famed musketeer possibly found in Dutch church
- Figure out How to Augment the Advantages of a Web-based Degree
